TD to Expand its U.S. Investment Banking Business and Capabilities with Acquisition of Cowen Inc. Click here for the Press Release

$500 Million

Ultragenyx Pharmaceutical

Exclusive Financial Advisor, July 2022

Royalty Purchase Agreement (Partial Monetization)

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

More Like This

Aug 2022
$60 Million

Sr. Secured Term Loan

Sole Placement Agent & Exclusive Financial Advisor

View Details
Jul 2022
$264.5 Million
Revolution Medicines logo

Follow-on Offering

Bookrunner

View Details
Jul 2022
$350 Million

Series A Private Placement

Exclusive Placement Agent

View Details